ARS Pharmaceuticals Submits Response to FDA Letter for Neffy
By Chris Wack
ARS Pharmaceuticals has submitted its response to the U.S. Food and Drug Administration for its New Drug Application of neffy epinephrine nasal spray for the treatment of Type I allergic reactions including anaphylaxis.
The submission follows receipt of a Complete Response Letter from the FDA in September 2023, which identified two additional requests: completion of a repeat dose pharmacokinetic/pharmacodynamic study of neffy under nasal allergen challenge (NAC) conditions, and completion of updated nitrosamine testing per the FDA's draft guidance issued in August 2023.
In February 2024, ARS Pharma successfully completed the repeat dosing study of neffy in seasonal allergic rhinitis under NAC conditions. ARS Pharma also completed the nitrosamine testing requested with no measurable levels of nitrosamines detected.
The original neffy NDA was submitted in August 2022. In May 2023, the FDA Advisory Committee determined a favorable benefit-risk profile for neffy: 16:6 for adults and 17:5 for children. No committee member requested a repeat dose study during allergen-induced allergic rhinitis.
ARS Pharma sees an FDA review period of up to six months, and the PDUFA date is anticipated to be Oct. 2, 2024, based on the submission receipt date of April 2, 2024.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 03, 2024 09:33 ET (13:33 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings, Is Coinbase Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy
-
Energy Transfer Earnings: M&A Drives Guidance Increase In Solid Quarter
-
The Best Healthcare Stocks to Buy
-
Going Into Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?